Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29059942 | 0.81 | CYP1A2 (0.53) | CYP1A2HDAC1HDAC8PDPK1CYP2D6 | |
| SCHEMBL17260640 | 0.79 | CYP1A2 (0.67) | CYP1A2HDAC1HDAC8SIGMAR1CYP2D6 | |
| SCHEMBL6771529 | 0.77 | CYP1A2 (0.63) | CYP1A2HDAC1HDAC8SIGMAR1CYP2D6 | |
| SCHEMBL20898006 | 0.76 | HDAC1 (0.62) | CYP1A2HDAC1HDAC8PDPK1CYP2D6 | |
| SCHEMBL9753260 | 0.76 | EPHX1 (0.41) | CYP2C19CTSBCTSSCTSKKDM4E | |
| SCHEMBL17578809 | 0.75 | HDAC1 (0.65) | CYP1A2HDAC1HDAC8SIGMAR1HCAR2 | |
| SCHEMBL27862045 | 0.75 | CYP1A2 (0.69) | CYP1A2HDAC1HDAC8SIGMAR1PDPK1 | |
| SCHEMBL2914935 | 0.75 | L3MBTL1 (0.49) | CYP1A2CTSBCTSSCTSKSLC6A3 | |
| SCHEMBL5182845 | 0.74 | CYP1A2 (0.73) | CYP1A2HDAC1HDAC8SIGMAR1PDPK1 | |
| SCHEMBL7356219 | 0.73 | HTR2A (0.51) | CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224164-B1 | HYDROXAMIC ACID DERIVATIVE AS INHIBITOR OF THE FORMATION OF SOLUBLE HUMAN CD23 | SMITHKLINE BEECHAM PLC (GB) | 2004-12-08 | — | — | EP | disclosed |
| EP-1089963-B1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE | SMITHKLINE BEECHAM PLC (GB) | 2004-06-16 | — | — | EP | disclosed |
| US-20040077727-A1 | Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23 | SMITHKLINE BEECHAM P.L.C. | 2004-04-22 | — | — | US | disclosed |
| US-6673965-B1 | AUTOIMMUNE DISEASE, INFLAMMATION, ALLERGY; IN-VIVO ABSORPTION BIOAVAILABILITY VIA THE ORAL ROUTE; DEPROTECTING, REACTING WITH HYDROXYLAMINE; N'-(4-(N-HYDROXYAMINO)-3S-ISOPROPOXY-2R-(2-NAPHTHYLMETHYL) SUCCINYL)-S-TERT-LEUCINE METHYLAMIDE | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-06 | — | — | US | disclosed |
| US-6458779-B1 | TREATMENT OF CONDITIONS ASSOCIATED WITH EXCESS PRODUCTION OF SOLUBLE CD23 (S-CD23) SUCH AS AUTOIMMUNE DISEASE AND ALLERGY. THE COMPOUNDS OF THE INVENTION ARE ALSO INHIBITORS OF THE RELEASE OF TUMOUR NECROSIS FACTOR (TNF). | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-01 | — | — | US | disclosed |
| EP-1089963-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067201-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE | SMITHKLINE BEECHAM PLC (GB) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077727-A1 | Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23 | CD2, CD22, CD2BP2 | CYP1A2 3133/4885HDAC1 54/4885HDAC8 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.